Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review

In comparison to the general population, lung cancer patients are more likely to suffer from severe Coronavirus disease (COVID-19) and associated mortality. Considering this increased risk, and in order to prevent symptoms and severe disease, patients with lung cancer have been prioritized for COVID...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodilla, Ananda M., Tavolacci, Sooyun, Cagan, Jazz, Shah, Tanay, Mittan, Sandeep, Mack, Philip C., Hirsch, Fred R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223259/
https://www.ncbi.nlm.nih.gov/pubmed/37243073
http://dx.doi.org/10.3390/vaccines11050969
_version_ 1785049898856480768
author Rodilla, Ananda M.
Tavolacci, Sooyun
Cagan, Jazz
Shah, Tanay
Mittan, Sandeep
Mack, Philip C.
Hirsch, Fred R.
author_facet Rodilla, Ananda M.
Tavolacci, Sooyun
Cagan, Jazz
Shah, Tanay
Mittan, Sandeep
Mack, Philip C.
Hirsch, Fred R.
author_sort Rodilla, Ananda M.
collection PubMed
description In comparison to the general population, lung cancer patients are more likely to suffer from severe Coronavirus disease (COVID-19) and associated mortality. Considering this increased risk, and in order to prevent symptoms and severe disease, patients with lung cancer have been prioritized for COVID-19 vaccination primary and booster doses. Despite this, the pivotal clinical trials did not include these patients, which leaves open questions regarding vaccine efficacy and humoral immune response. This review outlines the findings of recent investigations into the humoral responses of lung cancer patients to COVID-19 vaccination, particularly the primary doses and first boost.
format Online
Article
Text
id pubmed-10223259
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102232592023-05-28 Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review Rodilla, Ananda M. Tavolacci, Sooyun Cagan, Jazz Shah, Tanay Mittan, Sandeep Mack, Philip C. Hirsch, Fred R. Vaccines (Basel) Review In comparison to the general population, lung cancer patients are more likely to suffer from severe Coronavirus disease (COVID-19) and associated mortality. Considering this increased risk, and in order to prevent symptoms and severe disease, patients with lung cancer have been prioritized for COVID-19 vaccination primary and booster doses. Despite this, the pivotal clinical trials did not include these patients, which leaves open questions regarding vaccine efficacy and humoral immune response. This review outlines the findings of recent investigations into the humoral responses of lung cancer patients to COVID-19 vaccination, particularly the primary doses and first boost. MDPI 2023-05-11 /pmc/articles/PMC10223259/ /pubmed/37243073 http://dx.doi.org/10.3390/vaccines11050969 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Rodilla, Ananda M.
Tavolacci, Sooyun
Cagan, Jazz
Shah, Tanay
Mittan, Sandeep
Mack, Philip C.
Hirsch, Fred R.
Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review
title Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review
title_full Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review
title_fullStr Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review
title_full_unstemmed Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review
title_short Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review
title_sort serological response to sars-cov-2 after covid-19 vaccination in lung cancer patients: short review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223259/
https://www.ncbi.nlm.nih.gov/pubmed/37243073
http://dx.doi.org/10.3390/vaccines11050969
work_keys_str_mv AT rodillaanandam serologicalresponsetosarscov2aftercovid19vaccinationinlungcancerpatientsshortreview
AT tavolaccisooyun serologicalresponsetosarscov2aftercovid19vaccinationinlungcancerpatientsshortreview
AT caganjazz serologicalresponsetosarscov2aftercovid19vaccinationinlungcancerpatientsshortreview
AT shahtanay serologicalresponsetosarscov2aftercovid19vaccinationinlungcancerpatientsshortreview
AT mittansandeep serologicalresponsetosarscov2aftercovid19vaccinationinlungcancerpatientsshortreview
AT mackphilipc serologicalresponsetosarscov2aftercovid19vaccinationinlungcancerpatientsshortreview
AT hirschfredr serologicalresponsetosarscov2aftercovid19vaccinationinlungcancerpatientsshortreview

Ejemplares similares